Fig. 7: SAR’336 induces Treg expansion in the blood and lymphoid organs in mice.
From: A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism
a C57BL6 mice were treated with 0.3 mg/kg SAR’336 subcutaneously. b Frequency of CD4+ Treg cells in blood, lymph nodes, spleen, and thymus was measured. Groups of 10-week-old C57BL6 mice (n = 4) were given a single dose of SAR’336 subcutaneously at 0.3 mg/kg or vehicle. Blood, spleen, and lymph nodes were collected at 3-, 8- or 14-days post dose. Flow cytometry was performed on whole blood and disaggregated cells from tissues to assess relative levels of Treg (CD4 + , CD25 + , FoxP3 +), CD4, CD8 and NK populations. Fold change was compared to an untreated baseline group (n = 4). CD3 cluster of differentiation 3, CD4 cluster of differentiation 4, CD25 cluster of differentiation 25, FoxP3 forkhead box protein 3, NK natural killer, SC subcutaneous, Treg regulatory T cell, WBC white blood cell. Mouse vector illustration credit: [baluchis]/stock.adobe.com.
